This is an automatically translated article.
Spasmebi drug with the main ingredient is Alverine citrate, which is a non-anticholinergic smooth muscle antispasmodic. Spasmebi is used in the treatment of pain caused by gastrointestinal smooth muscle spasms and primary dysmenorrhea. The following article provides you with information about the uses and notes when using Spasmebi.
1. What is Spasmebi?
Spasmebi is a non-anticholinergic smooth muscle antispasmodic. Spasmebi has the main active ingredient, Alverine citrate, which is prepared in the form of tablets with a strength of 40mg.
Pharmacology and mechanism of action
Alverine citrate has a specific direct effect against smooth muscle spasms in the gastrointestinal tract and uterus, but Alverine has no effect on blood vessels, heart and trachea when administered at therapeutic doses. treat. Recently, the effect of Alverine citrate in the gastrointestinal tract has been identified by 3 mechanisms: Decreased intestinal sensitivity; calcium channel blocker and serotonin 5HT1A receptor blocker. Pharmacokinetics
After Alverine citrate is absorbed from the gastrointestinal tract, it is rapidly metabolized to the active metabolite. Peak plasma concentrations are reached 1 to 1.5 hours after dosing. After that, the drug will be further metabolized to inactive substances and excreted in the urine.
2. Indications and contraindications of Spasmebi
2.1. Indications Spasmebi is indicated for use in the antispasmodic treatment of gastrointestinal smooth muscle such as: Irritable bowel syndrome, pain due to biliary spasm, appendicitis pain, colon diverticulum pain. Renal colic pain. Primary dysmenorrhea. 2.2. Contraindications Spasmebi is contraindicated for use in the following cases:
Hypersensitivity to Alverine or any other ingredient in Spasmebi. Intestinal obstruction or paralytic ileus. Intestinal obstruction due to feces. Loss of colon tone.
3. How to use Spasmebi
3.1. Dosage Spasmebi tablets are taken orally.
In adults (including the elderly): the dose is 1-3 tablets/time x 3 times/day. Children under 12 years of age should not use Spasmebi. 3.2. Spasmebi Overdosage and Management Overdose of Spasmebi may result in hypotension and symptoms of toxicity similar to atropine.
Treatment: similar to Atropin poisoning. Perform gastric lavage for the patient, and should give activated charcoal before performing gastric lavage. In addition, supportive measures should be taken to treat hypotension if symptoms are present. In case of overdose of Spasmebi, immediately go to the nearest medical facility for timely treatment.
3.3. Missing a dose of Spasmebi and what to do If you forget to take a dose of Spasmebi, take it as soon as possible. If it is almost time for the next dose of Spasmebi, skip the missed dose and take the next dose as scheduled. Also, do not double the dose of Spasmebi.
4. Undesirable effects when using Spasmebi
Side effects when using Spasmebi may be: Nausea, headache, itching, dizziness, rash, allergic reactions including anaphylaxis. Side effects from using Alverine are usually mild and do not require any treatment.
In case of rash, itching, need to stop Spasmebi and monitor for anaphylactic reactions, although very rare.
5. Note when using Spasmebi
Consult a doctor if symptoms persist, worsen or do not improve or the patient develops new symptoms after 2 days of treatment. Pregnancy: Although Alverine is not teratogenic, because of the limited evidence for safety in preclinical studies, Spasmebi should not be used in pregnant women. Lactation: Spasmebi should not be used during lactation due to limited data on the safety of Alverine in this population. Spasmebi is used in the treatment of pain caused by gastrointestinal smooth muscle spasms and primary dysmenorrhea. Do not use Spasmebi in children under 12 years of age. In case after 2 days of using the drug, if symptoms persist or appear new, you should consult your doctor for timely treatment.
